News from Visiopharm


Clinical User Group Meeting 2018 - Augment your Pathology

NEW DATE: February 28 - Marts 1, 2018

Ingeniørforeningen (The Danish Society of Engineers), IDA

Sign up here

 

 

New APP: p63+CK7/19, Invasive Tumor Detection (PDS)

The “p63+CK7/19, Invasive Tumor Detection (PDS)” APP provide means for distinguishing between invasive tumor and non-invasive tumor based on a slide physically double stained (PDS) with the myoepithelial cell nuclear marker p63 and the tumor marker CK7/19.

With VirtualDoubleStaining™ this APP can be combined with other APPs intended for analysis of biomarker expression within invasive tumor components.

For more information visit our APP Center

Explore our webinars

Check out one of our many useful and informative webinars

Click here

 

 

New APP: PD-L1 Melanoma

Programmed death-ligand 1 (PD-L1) is a transmembrane protein that binds to the inhibitory receptor programmed death 1 receptor (PD-1), causing a down regulation of immune responses. Tumor cells can upregulate PD-L1 expression and avoid being attacked by the body’s immune system, making an interruption of the PD-1/PD-L1 interaction an attractive method for assisting the immune system in destroying tumor cells.

For more information visit our APP Center

New APP: PD-L1 Lung Cancer

PD-L1 is typically expressed on normal cells but has been observed in immune cells and tumor cells while PD-1 is typically expressed on cytotoxic T-cells and other immune cells. Tumor cells can upregulate PD-L1 expression and avoid being attacked by the body’s immune system, making an interruption of the PD-1/PD-L1 interaction an attractive method for assisting the immune system in destroying tumor cells.

For more information visit our APP Center

Sign up to our newsletter
* indicates required
Are you a current customer
 

Visiopharm quantitative digital pathology solutions provide pathologists and scientists with a flexible, powerful suite of software to quantify relevant tissue properties in a fast, objective and reproducible way.

Learn more about us

Visit our APP center

The worlds largest and fastest growing

Visit the complete app center

Publications

Visiopharm software is featured in over 1200 international scientific publications. They are based on collaborations with leading scientists in hospitals, biopharmaceutical companies and research institutions around the world. Select a main category to access the publication list.